

Consortium

14 main beneficiaries + 7 Affiliated entities
from 13 EU countries and 1 non-EU country

Project duration

40 months, February 2024 – June 2027

Estimated cost

18
€ **1.874.996,31** with an EU contribution
of € 1.499.997,06



Scan the QRcode and visit the project
website: <https://gapp-pro.eu/>.

Follow us on [LinkedIn](#).



BENEFICIARIES

ISS/CNT-CNS, Istituto Superiore Di Sanità, Centro Nazionale Trapianti, Centro Nazionale Sangue, Italy | **AGES**, Osterreichische Agentur Fur Gesundheit Und Ernahrungssicherheit Gmbh, Austria | **MOH HR**, Ministarstvo Zdravstva Republike Hrvatske, Croatia | **MPHS**, Ministry Of Health Of The Republic Of Cyprus, Cyprus | **STPS**, Styrelsen For Patientsikkerhed, Denmark | **ABM**, Agence De La Biomedecine, France | **HTO**, Hellenic Transplant Organization, Greece | **NNGYK**, Nemzeti Nepegeszseguyi Es Gyogyszereszeti Kozpont, Hungary | **HPRA**, Health Products Regulatory Authority, Ireland | **TRIP**, Stichting Trip Transfusie En Transplantatiesreacties In Patienten, Netherlands | **PUMS**, Uniwersytet Medyczny Im Karola Marcinkowskiego W Poznaniu, Poland | **SZU**, Slovenska Zdravotnicka Univerzita V Bratislave, Slovakia | **OCATT**, Servei Catala De La Salut, Spain | **UTCC**, Specialized State Institution "Ukrainian Transplant Coordination Center", Ukraine

AFFILIATED ENTITIES

ANSM, Agence Nationale De Securite Du Medicament Et Des Produits De Sante, France | **OVSZ**, Orszagos Verellato Szolgalat, Hungary | **DPC**, Del-Pesti Centrumkorhaz-Orszagos Hematologiai Es Infektologiai Intezet, Hungary | **BST**, Banc De Sang I Teixits, Spain | **ONT**, Organizacion Nacional De Trasplantes, Spain | **MOH ES**, Ministerio De Sanidad, Spain | **TICSALUT**, Fundacio Ticsalut, Spain

GAPP-PRO, Piloting GAPP model approach for assessing and authorizing novel substances of human origin preparation PROcess, is a project co-funded by the Health Programme of the European Union. Grant Agreement 101128035 – EU4H-2022-JA-07, February 2024 – June 2027. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.



Piloting GAPP model approach for
assessing and authorizing novel substances
of human origin preparation PROcess

